CN102648752A - 一种适于膳食失衡人群有降血糖功能的工程米及制备方法 - Google Patents
一种适于膳食失衡人群有降血糖功能的工程米及制备方法 Download PDFInfo
- Publication number
- CN102648752A CN102648752A CN2012101312618A CN201210131261A CN102648752A CN 102648752 A CN102648752 A CN 102648752A CN 2012101312618 A CN2012101312618 A CN 2012101312618A CN 201210131261 A CN201210131261 A CN 201210131261A CN 102648752 A CN102648752 A CN 102648752A
- Authority
- CN
- China
- Prior art keywords
- rice
- engineering rice
- engineering
- powder
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000007164 Oryza sativa Nutrition 0.000 title claims abstract description 42
- 235000009566 rice Nutrition 0.000 title claims abstract description 42
- 239000008280 blood Substances 0.000 title claims abstract description 30
- 210000004369 blood Anatomy 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 241000209094 Oryza Species 0.000 title abstract description 38
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title abstract description 8
- 239000008103 glucose Substances 0.000 title abstract description 8
- 235000005911 diet Nutrition 0.000 title abstract description 5
- 230000037213 diet Effects 0.000 title abstract description 5
- 239000000843 powder Substances 0.000 claims abstract description 34
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 22
- 235000010445 lecithin Nutrition 0.000 claims abstract description 22
- 239000000787 lecithin Substances 0.000 claims abstract description 22
- 229940067606 lecithin Drugs 0.000 claims abstract description 22
- 239000002994 raw material Substances 0.000 claims abstract description 22
- 229920001202 Inulin Polymers 0.000 claims abstract description 21
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 21
- 229940029339 inulin Drugs 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 235000000832 Ayote Nutrition 0.000 claims abstract description 18
- 235000009854 Cucurbita moschata Nutrition 0.000 claims abstract description 18
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims abstract description 18
- 235000015136 pumpkin Nutrition 0.000 claims abstract description 18
- 229920002752 Konjac Polymers 0.000 claims abstract description 17
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims abstract description 17
- 239000011648 beta-carotene Substances 0.000 claims abstract description 17
- 235000013734 beta-carotene Nutrition 0.000 claims abstract description 17
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims abstract description 17
- 229960002747 betacarotene Drugs 0.000 claims abstract description 17
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims abstract description 17
- 108010073771 Soybean Proteins Proteins 0.000 claims abstract description 15
- 239000000252 konjac Substances 0.000 claims abstract description 15
- 235000019710 soybean protein Nutrition 0.000 claims abstract description 15
- 238000004806 packaging method and process Methods 0.000 claims abstract description 7
- 229920002581 Glucomannan Polymers 0.000 claims description 16
- 239000000835 fiber Substances 0.000 claims description 16
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims description 15
- 229940046240 glucomannan Drugs 0.000 claims description 15
- 244000247812 Amorphophallus rivieri Species 0.000 claims description 14
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims description 14
- 235000007319 Avena orientalis Nutrition 0.000 claims description 14
- 244000075850 Avena orientalis Species 0.000 claims description 14
- 235000010485 konjac Nutrition 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 240000001980 Cucurbita pepo Species 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 235000012054 meals Nutrition 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 238000001125 extrusion Methods 0.000 claims description 7
- 238000000465 moulding Methods 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 2
- 240000007594 Oryza sativa Species 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 15
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 201000001421 hyperglycemia Diseases 0.000 abstract description 12
- 235000016709 nutrition Nutrition 0.000 abstract description 12
- 235000012000 cholesterol Nutrition 0.000 abstract description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 6
- 240000004244 Cucurbita moschata Species 0.000 abstract description 5
- 206010022489 Insulin Resistance Diseases 0.000 abstract description 5
- 230000000291 postprandial effect Effects 0.000 abstract description 4
- 235000021329 brown rice Nutrition 0.000 abstract description 3
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 102000017011 Glycated Hemoglobin A Human genes 0.000 abstract 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 235000019823 konjac gum Nutrition 0.000 abstract 1
- 235000019895 oat fiber Nutrition 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 22
- 102000004877 Insulin Human genes 0.000 description 11
- 108090001061 Insulin Proteins 0.000 description 11
- 229940125396 insulin Drugs 0.000 description 11
- 230000035764 nutrition Effects 0.000 description 10
- 230000001228 trophic effect Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 235000013339 cereals Nutrition 0.000 description 8
- 235000013325 dietary fiber Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000030136 gastric emptying Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 208000013016 Hypoglycemia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000021258 carbohydrate absorption Nutrition 0.000 description 2
- 210000004913 chyme Anatomy 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000006377 glucose transport Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229940038580 oat bran Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004904 shortening Methods 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000020131 Acid-base disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000004237 Crocus Nutrition 0.000 description 1
- 241000596148 Crocus Species 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 206010053695 Diabetic dermopathy Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 244000130270 Fagopyrum tataricum Species 0.000 description 1
- 235000014693 Fagopyrum tataricum Nutrition 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 208000009451 Hyperglycemic Hyperosmolar Nonketotic Coma Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 206010049287 Lipodystrophy acquired Diseases 0.000 description 1
- 241000406668 Loxodonta cyclotis Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 229940062310 avandia Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 229960003709 kallidinogenase Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000006132 lipodystrophy Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000004203 pancreatic function Effects 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
Abstract
Description
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210131261.8A CN102648752B (zh) | 2012-05-02 | 2012-05-02 | 一种适于膳食失衡人群有降血糖功能的工程米及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210131261.8A CN102648752B (zh) | 2012-05-02 | 2012-05-02 | 一种适于膳食失衡人群有降血糖功能的工程米及制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102648752A true CN102648752A (zh) | 2012-08-29 |
CN102648752B CN102648752B (zh) | 2014-05-21 |
Family
ID=46691004
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210131261.8A Active CN102648752B (zh) | 2012-05-02 | 2012-05-02 | 一种适于膳食失衡人群有降血糖功能的工程米及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102648752B (zh) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105231462A (zh) * | 2015-11-19 | 2016-01-13 | 刘庆华 | 复方降糖营养粉 |
CN105249466A (zh) * | 2015-11-19 | 2016-01-20 | 刘庆华 | 降糖食物组合物 |
CN106421374A (zh) * | 2016-12-13 | 2017-02-22 | 四川西奈生物科技有限公司 | 治疗糖尿病的中药组合物及其使用方法 |
CN107149082A (zh) * | 2016-03-02 | 2017-09-12 | 上海宣泰生物科技有限公司 | 一种防治糖尿病的高抗性淀粉含量米粉的组合物 |
CN107373375A (zh) * | 2017-07-31 | 2017-11-24 | 东北农业大学 | 一种抗氧化工程再造米的制备方法 |
CN107495099A (zh) * | 2017-09-18 | 2017-12-22 | 王承波 | 米制品及其制备方法 |
CN109303262A (zh) * | 2018-12-04 | 2019-02-05 | 于星洋 | 一种适合糖尿病及高血糖人群食用的复合大米及其制备方法 |
CN109730244A (zh) * | 2018-03-06 | 2019-05-10 | 丽睿客信息科技(北京)有限公司 | 纳微米级营养主食及其制备方法 |
CN112137006A (zh) * | 2019-06-26 | 2020-12-29 | 中粮集团有限公司 | 血糖调控包埋复配米加工方法和加工装置以及血糖调控包埋复配米 |
CN112602928A (zh) * | 2020-12-18 | 2021-04-06 | 湖州草本连生物科技有限公司 | 一种具有降压、降脂、降血糖的营养粉及其制备方法 |
CN113826824A (zh) * | 2021-08-24 | 2021-12-24 | 福州康为网络技术有限公司 | 一种缓释营养功能型综合调控改善糖尿病的重组米及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1123097A (zh) * | 1994-11-23 | 1996-05-29 | 淮安市神农保健食品公司 | “降糖糊”及其生产工艺 |
CN101019653A (zh) * | 2007-03-27 | 2007-08-22 | 范守华 | 一种具有稳定餐后血糖的保健面条及其制备方法 |
CN101138427A (zh) * | 2006-09-07 | 2008-03-12 | 董忠蓉 | 具有靶向性的魔芋人造米及其制作方法 |
CN101564159A (zh) * | 2009-02-25 | 2009-10-28 | 田向东 | 一种降低高血压和糖尿病的食品及其制备方法 |
CN102077936A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种糖尿病患者专用的海洋特膳食品 |
-
2012
- 2012-05-02 CN CN201210131261.8A patent/CN102648752B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1123097A (zh) * | 1994-11-23 | 1996-05-29 | 淮安市神农保健食品公司 | “降糖糊”及其生产工艺 |
CN101138427A (zh) * | 2006-09-07 | 2008-03-12 | 董忠蓉 | 具有靶向性的魔芋人造米及其制作方法 |
CN101019653A (zh) * | 2007-03-27 | 2007-08-22 | 范守华 | 一种具有稳定餐后血糖的保健面条及其制备方法 |
CN101564159A (zh) * | 2009-02-25 | 2009-10-28 | 田向东 | 一种降低高血压和糖尿病的食品及其制备方法 |
CN102077936A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种糖尿病患者专用的海洋特膳食品 |
Non-Patent Citations (2)
Title |
---|
陈厚荣等: "杂粮营养工程米的干燥及蒸煮特性研究", 《食品科学》 * |
陈厚荣等: "降低挤压杂粮营养工程米黏附性的工艺优化", 《食品科学》 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105231462B (zh) * | 2015-11-19 | 2018-02-13 | 刘庆华 | 复方降糖营养粉 |
CN105249466A (zh) * | 2015-11-19 | 2016-01-20 | 刘庆华 | 降糖食物组合物 |
CN105249466B (zh) * | 2015-11-19 | 2018-02-13 | 刘庆华 | 降糖食物组合物 |
CN105231462A (zh) * | 2015-11-19 | 2016-01-13 | 刘庆华 | 复方降糖营养粉 |
CN107149082A (zh) * | 2016-03-02 | 2017-09-12 | 上海宣泰生物科技有限公司 | 一种防治糖尿病的高抗性淀粉含量米粉的组合物 |
CN106421374A (zh) * | 2016-12-13 | 2017-02-22 | 四川西奈生物科技有限公司 | 治疗糖尿病的中药组合物及其使用方法 |
CN107373375A (zh) * | 2017-07-31 | 2017-11-24 | 东北农业大学 | 一种抗氧化工程再造米的制备方法 |
CN107495099A (zh) * | 2017-09-18 | 2017-12-22 | 王承波 | 米制品及其制备方法 |
CN109730244A (zh) * | 2018-03-06 | 2019-05-10 | 丽睿客信息科技(北京)有限公司 | 纳微米级营养主食及其制备方法 |
CN109303262A (zh) * | 2018-12-04 | 2019-02-05 | 于星洋 | 一种适合糖尿病及高血糖人群食用的复合大米及其制备方法 |
CN112137006A (zh) * | 2019-06-26 | 2020-12-29 | 中粮集团有限公司 | 血糖调控包埋复配米加工方法和加工装置以及血糖调控包埋复配米 |
CN112602928A (zh) * | 2020-12-18 | 2021-04-06 | 湖州草本连生物科技有限公司 | 一种具有降压、降脂、降血糖的营养粉及其制备方法 |
CN113826824A (zh) * | 2021-08-24 | 2021-12-24 | 福州康为网络技术有限公司 | 一种缓释营养功能型综合调控改善糖尿病的重组米及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102648752B (zh) | 2014-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102648752B (zh) | 一种适于膳食失衡人群有降血糖功能的工程米及制备方法 | |
AU2017101389A4 (en) | Specialized flour for nutrition meals for diabetes and preparation method and use thereof | |
CN104286849A (zh) | 一种糖尿病专用型肠内营养多聚合剂 | |
CN110326780A (zh) | 一种具有降血糖功能的营养代餐及其制备方法 | |
CN101715913B (zh) | 一种调节血脂的胶囊及其生产制作工艺 | |
CN105211884A (zh) | 供糖尿病肾病患者透析后食用的营养组合物及其制备方法 | |
CN101473953A (zh) | 净血排毒组合食品及其加工方法和应用 | |
CN103689375A (zh) | 一种适合糖尿病人的面条配方及其加工方法 | |
CN103431392B (zh) | 一种供糖尿病患者食用的复合海洋特膳食品 | |
CN104585746A (zh) | 一种供糖尿病人食用的特殊膳食食品生产方法 | |
CN102461587A (zh) | 预防糖尿病用富硒桑叶黑粮面制食品 | |
CN105124347A (zh) | 一种辣木降血糖组合物及其制备方法 | |
CN104605346B (zh) | 一种面粉及其制备方法 | |
CN109043553A (zh) | 一种妊娠糖尿病患者食用的特殊食品及其制备方法 | |
CN113018364A (zh) | 一种具有降血糖功能的组合物和饼干 | |
CN108576827A (zh) | 围手术期营养食品 | |
KR101326002B1 (ko) | 당뇨병 개선을 위한 혈당 저하 및 조절용 조성물 | |
CN112189839A (zh) | 一种辅助降血脂组合物及其应用 | |
CN1101133C (zh) | 具有降血糖作用的缮食纤维百乐饼干的配方及其生产工艺 | |
CN103404875B (zh) | 一种供心血管疾病患者食用的复合海洋特膳食品 | |
CN109043555A (zh) | 一种高血糖患者食用的特殊食品及其制备方法 | |
CN110101020A (zh) | 一种糖尿病全营养素配方食品 | |
CN114586973A (zh) | 一种低gi全营养代餐粉及其制备方法 | |
CN113424850A (zh) | 一种含有核桃菇提取物的无糖蛋糕 | |
KR20110014418A (ko) | 당뇨환자의 혈당조절용 고추장 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: PERFECT (CHINA) CO., LTD. Effective date: 20121226 |
|
C10 | Entry into substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Duan Shenglin Inventor after: Cai Muyi Inventor after: Hu Ruilian Inventor after: Li Chenyue Inventor after: Dong Zhe Inventor after: Liu Yanqiao Inventor after: Wang Xue Inventor after: Liu Shiwei Inventor after: Liu Jie Inventor before: Duan Shenglin Inventor before: Cai Muyi Inventor before: Dong Zhe Inventor before: Liu Yanqiao Inventor before: Wang Xue Inventor before: Liu Shiwei Inventor before: Liu Jie |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: DUAN SHENGLIN CAI MUYI DONG ZHE LIU YANQIAO WANG XUE LIU SHIWEI LIU JIE TO: DUAN SHENGLIN CAI MUYI HU RUILIAN LI CHENYUE DONG ZHE LIU YANQIAO WANG XUE LIU SHIWEI LIU JIE |
|
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20121226 Address after: 100027 Beijing city Chaoyang District Xiaoyun Road No. 32 Applicant after: CHINA NATIONAL Research Institute OF FOOD AND FERMENTATION INDUSTRIES Applicant after: PERFECT (CHINA) Co.,Ltd. Address before: 100027 Beijing city Chaoyang District Xiaoyun Road No. 32 Applicant before: CHINA NATIONAL Research Institute OF FOOD AND FERMENTATION INDUSTRIES |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: No. 32, Beijing Xiaoyun Road, Chaoyang District, Beijing Co-patentee after: PERFECT (CHINA) Co.,Ltd. Patentee after: CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES Co.,Ltd. Address before: No. 32, Beijing Xiaoyun Road, Chaoyang District, Beijing Co-patentee before: PERFECT (CHINA) Co.,Ltd. Patentee before: CHINA NATIONAL Research Institute OF FOOD AND FERMENTATION INDUSTRIES |
|
TR01 | Transfer of patent right |
Effective date of registration: 20190530 Address after: No. 32, Beijing Xiaoyun Road, Chaoyang District, Beijing Co-patentee after: PERFECT (GUANGDONG) COMMODITY Co.,Ltd. Patentee after: CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES Co.,Ltd. Co-patentee after: YANGZHOU PERFECT COMMODITY CO.,LTD. Co-patentee after: PERFECT (CHINA) Co.,Ltd. Address before: No. 32, Beijing Xiaoyun Road, Chaoyang District, Beijing Co-patentee before: PERFECT (CHINA) Co.,Ltd. Patentee before: CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES Co.,Ltd. |
|
TR01 | Transfer of patent right |